Perioperative High-Dose-Rate Brachytherapy in the Treatment of Recurrent Malignant Gliomas

Abstract

Perioperative brachytherapy has proven to be safe and well tolerated in patients with recurrent malignant glioma. No severe toxicity was reported, and the treatment has proven to be effective in symptomatic recurrences of malignant gliomas.

Patterns of Intracranial Glioblastoma Recurrence After Aggressive Surgical Resection and Adjuvant Management: Retrospective Analysis of 43 Cases

“…4,20,33,37,48) The progression of glioblastoma after treatment in up to 97% of cases occurs either from the bulk of the mass or within 20 mm from the border of its enhanced part identifiable on T 1 -weighted magnetic resonance (MR) imaging, and the presence of such local recurrence may be associated with impaired prognosis. 2,3,12,13,23,25,32,34,35,43,44,54) Therefore, various methods for improvement of tumor control at the time of both initial and salvage treatment have been proposed, such as inclusion of the marginal brain tissue in the high dose area during FRT, 4,17,20,26,31-33, 35,49,50) additional dose boost with stereotactic radiosurgery, 14,18,41) brachytherapy, 10,36,43) implantation of Gliadel wafers (Guilford Pharmaceuticals Inc., Baltimore, Maryland, USA), 53) or various types of intralesional immunotherapy. 7,42) The majority of studies on progression of intracranial gliomas after initial treatment have included many cases with incomplete surgical tumor removal.…”

Aplastic Anemia as a Cause of Death in a Patient with Glioblastoma Multiforme Treated with Temozolomide

“…Unilateral blindness and misunderstanding Strahlenther Onkol 2010 of a written word is the sign of infliction of the occipital lobe. The length of patient's survival with glioblastoma multiforme is dependent on many independent factors -age, neurological status, cognitive functions, the type of tumor, its size and location [2,3,8,13].…”

MRI during radiotherapy of glioblastoma

“…Without treatment, glioblastoma are usually fatal within a few weeks to several months [1][2][3][4][5][6][7]. Current therapeutic strategies with surgery followed by local radiotherapy and simultaneous as well as adjuvant chemotherapy have increased median life expectancy from 12.1 to 14.6 months [8][9][10][11]. A number of prognostic factors are known today, like general patient condition, age (>/< 65 years) [12,13] or extent of resection [14].…”